Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

40
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
40

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

CD4<sup>+</sup> T cells reactive to Epstein-Barr virus late lytic antigens are enriched in individuals with multiple sclerosis.

Science translational medicine·2026
Same author

Gestational Age as a Risk Factor for Neurodevelopmental Disabilities: Exploring Causal Pathways.

Paediatric and perinatal epidemiology·2026
Same author

Challenges and future directions for multiple sclerosis after the 2024 McDonald diagnostic criteria.

Nature medicine·2026
Same author

Reduced cortical gyrification in type 1 diabetes is associated with white matter integrity loss and cognitive decline.

Metabolic brain disease·2026
Same author

Global Access to Diagnostic Paraclinical Testing Incorporated in the 2024 Revised McDonald Criteria: Disparities and Opportunity.

Neurology. Clinical practice·2026
Same author

Cortical gray-white matter contrast alterations precede amyloid-β positivity and macrostructural changes in older adults without dementia.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026

相关实验视频

Updated: Sep 15, 2025

Author Spotlight: Unveiling the Pathway Linking Obesity to Autoimmune Inflammation in Multiple Sclerosis
08:17

Author Spotlight: Unveiling the Pathway Linking Obesity to Autoimmune Inflammation in Multiple Sclerosis

Published on: February 23, 2024

4.7K

血清α-烯酸和长期多发性硬化症活动和进展.

Marianna Cortese1, Xiaojing Peng1, Gilles Edan2

  • 1Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA.

Neurology
|July 17, 2025
PubMed
概括

更高的阿尔法-烯酸 (ALA) 摄入量与减少多发性硬化症 (MS) 风险和疾病进展的减缓有关. 这项研究证实了ALA的存在.

更多相关视频

Author Spotlight: Novel Assay for Studying B-Cell Responses in Multiple Sclerosis Research
05:55

Author Spotlight: Novel Assay for Studying B-Cell Responses in Multiple Sclerosis Research

Published on: December 1, 2023

971
Positron Emission Tomography Imaging for In Vivo Measuring of Myelin Content in the Lysolecithin Rat Model of Multiple Sclerosis
08:40

Positron Emission Tomography Imaging for In Vivo Measuring of Myelin Content in the Lysolecithin Rat Model of Multiple Sclerosis

Published on: February 28, 2021

4.2K

相关实验视频

Last Updated: Sep 15, 2025

Author Spotlight: Unveiling the Pathway Linking Obesity to Autoimmune Inflammation in Multiple Sclerosis
08:17

Author Spotlight: Unveiling the Pathway Linking Obesity to Autoimmune Inflammation in Multiple Sclerosis

Published on: February 23, 2024

4.7K
Author Spotlight: Novel Assay for Studying B-Cell Responses in Multiple Sclerosis Research
05:55

Author Spotlight: Novel Assay for Studying B-Cell Responses in Multiple Sclerosis Research

Published on: December 1, 2023

971
Positron Emission Tomography Imaging for In Vivo Measuring of Myelin Content in the Lysolecithin Rat Model of Multiple Sclerosis
08:40

Positron Emission Tomography Imaging for In Vivo Measuring of Myelin Content in the Lysolecithin Rat Model of Multiple Sclerosis

Published on: February 28, 2021

4.2K

科学领域:

  • 神经学 神经学
  • 营养科学 营养科学
  • 流行病学 流行病学

背景情况:

  • 多发性硬化症 (MS) 是一种慢性神经系统疾病.
  • 饮食中摄入的阿尔法-烯酸 (ALA),一种omega-3脂肪酸,可能会影响MS风险和进展.
  • 之前的研究表明,ALA在MS中起着保护作用.

研究的目的:

  • 调查血清中ALA和其他多不和脂肪酸 (PUFA) 的水平与MS结果之间的关联.
  • 根据脂肪酸概况预测多发性硬化症的活性和进展.
  • 在临床发病后的11年时间内检查这些关联.

主要方法:

  • 在BENEFIT临床试验中的前性队列研究.
  • 使用气相色谱进行血清脂肪酸分析.
  • 考克斯,负二项式和线性回归模型来评估与MS结果的关联.

主要成果:

  • 较高的血清ALA基线水平与临床确定的MS (CDMS) 和5年和11年复发的风险明显降低有关.
  • ALA水平与MS功能复合分数的较慢下降相关,这表明残疾进展较小.
  • 没有发现其他脂肪酸与CDMS风险或长期进展的显著关联.

结论:

  • 血清ALA水平升高与MS诊断和复发风险降低有关.
  • ALA 可能在多发性硬化症的进展和残疾中发挥保护作用.
  • 血清脂肪酸概况,特别是ALA,可以作为MS风险和预后的生物标志物.